Wall Street analysts forecast that ANI Pharmaceuticals Inc (NASDAQ:ANIP) will announce sales of $52.49 million for the current quarter, according to Zacks. Two analysts have provided estimates for ANI Pharmaceuticals’ earnings, with estimates ranging from $51.70 million to $53.27 million. ANI Pharmaceuticals posted sales of $38.21 million in the same quarter last year, which would indicate a positive year over year growth rate of 37.4%. The firm is scheduled to issue its next quarterly earnings results on Thursday, March 1st.

On average, analysts expect that ANI Pharmaceuticals will report full-year sales of $52.49 million for the current fiscal year, with estimates ranging from $181.20 million to $182.83 million. For the next financial year, analysts expect that the firm will post sales of $215.57 million per share, with estimates ranging from $207.53 million to $223.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow ANI Pharmaceuticals.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The company had revenue of $48.16 million for the quarter, compared to the consensus estimate of $48.12 million. During the same quarter last year, the company earned $1.09 earnings per share. The firm’s revenue for the quarter was up 25.0% compared to the same quarter last year.

Several equities research analysts have weighed in on ANIP shares. ValuEngine raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, November 16th. Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a report on Tuesday, November 7th. Finally, Canaccord Genuity reissued a “buy” rating on shares of ANI Pharmaceuticals in a report on Thursday, November 2nd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $70.50.

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA lifted its holdings in shares of ANI Pharmaceuticals by 44.6% during the second quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock worth $101,000 after purchasing an additional 664 shares during the period. SG Americas Securities LLC acquired a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $197,000. Violich Capital Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $217,000. Municipal Employees Retirement System of Michigan lifted its holdings in shares of ANI Pharmaceuticals by 132.0% during the second quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $197,000 after purchasing an additional 2,390 shares during the period. Finally, Crossmark Global Holdings Inc. acquired a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $226,000. 55.05% of the stock is owned by hedge funds and other institutional investors.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) opened at $65.47 on Wednesday. ANI Pharmaceuticals has a 12-month low of $42.23 and a 12-month high of $74.70. The firm has a market capitalization of $772.13, a PE ratio of 19.78 and a beta of 2.91. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45.

WARNING: “Brokerages Expect ANI Pharmaceuticals Inc (ANIP) Will Announce Quarterly Sales of $52.49 Million” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/brokerages-expect-ani-pharmaceuticals-inc-anip-will-announce-quarterly-sales-of-52-49-million/1774367.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.